Medicis Announces Second Quarter 2008 Conference Call and Webcast

SCOTTSDALE, Ariz., July 31, 2008 (PRIME NEWSWIRE) -- Medicis (NYSE:MRX) today
announced it expects to report 2008 second quarter financial results after the
market closes on Tuesday, August 5, 2008. Medicis will host a conference call at
5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) to review the June 30, 2008,
second quarter financial results, as well as provide an update on other business
matters of the Company. A live webcast will be available at
http://www.medicis.com/company/index.asp. The webcast will be archived on the
Company's website for two business days following the live call.

Callers should dial in approximately 10 minutes prior to the start of the call.
No reservation is necessary to participate on the call. The phone number to join
the conference call is +1 (877) 567-5763 (U.S. and Canada) or +1 (706) 679-4760
(international and local). The access code for the live call is 57660299. For
investors unable to participate in the live call, a replay will be available
soon after the live call. The phone number to access the replay is +1 (800)
642-1687 (U.S. and Canada) or +1 (706) 645-9291 (international and local). The
access code for the replay is 57660299. The replay will be available for two
business days following the live call.

About Medicis

Medicis is the leading independent specialty pharmaceutical company in the
United States focusing primarily on the treatment of dermatological and
aesthetic conditions. The Company is dedicated to helping patients attain a
healthy and youthful appearance and self-image. Medicis has leading branded
prescription products in a number of therapeutic and aesthetic categories. The
Company's products have earned wide acceptance by both physicians and patients
due to their clinical effectiveness, high quality and cosmetic elegance.

The Company's products include the prescription brands RESTYLANE(R) (hyaluronic
acid), PERLANE(R) (hyaluronic acid), DYNACIN(R) (minocycline HCl), LOPROX(R)
(ciclopirox), PLEXION(R) (sodium sulfacetamide 10% and sulfur 5%), SOLODYN(R)
(minocycline HCl, USP) Extended Release Tablets, TRIAZ(R) (benzoyl peroxide),
LIDEX(R) (fluocinonide) Cream 0.05%, VANOS(R) (fluocinonide) Cream 0.1%, and
ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R)
(sodium phenylbutyrate) Tablets and Powder and AMMONUL(R) (sodium phenylacetate
and sodium benzoate) Injection 10%/10%, prescription products indicated in the
treatment of Urea Cycle Disorder, and the over-the-counter brand ESOTERICA(R).
For more information about Medicis, please visit the Company's website at
www.medicis.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act. All statements included in this
press release that address activities, events or developments that Medicis
expects, believes or anticipates will or may occur in the future are
forward-looking statements. These statements are based on certain assumptions
made by Medicis based on its experience and perception of historical trends,
current conditions, expected future developments and other factors it believes
are appropriate in the circumstances. No assurances can be given, however, that
these activities, events or developments will occur or that such results will be
achieved. Such statements are subject to a number of assumptions, risks and
uncertainties, many of which are beyond the control of Medicis. Several of these
risks are outlined in the Company's most recent annual report on Form 10-K for
the year ended December 31, 2007, and other documents we file with the
Securities and Exchange Commission. Forward-looking statements represent the
judgment of Medicis' management as of the date of this release, and Medicis
disclaims any intent or obligation to update any forward-looking statements
contained herein, which speak as of the date hereof.

NOTE: Full prescribing information for any Medicis prescription product is
available by contacting the Company. RESTYLANE(R) and PERLANE(R) are trademarks
of HA North American Sales AB, a subsidiary of Medicis Pharmaceutical
Corporation. All other marks are the property of Medicis or its Affiliates.

-0-
CONTACT: Medicis
Kara Stancell
(480) 291-5854